Apyx Medical Q2 revenue $11.4M, net loss $3.8M; raises FY2025 revenue guidance to $50-52M

Apyx Medical Corp

Q2 total revenue $11.4M vs $12.1M YoY; Advanced Energy flat at $9.7M, OEM down 28.5% to $1.7M.
Net loss attributable to stockholders $3.8M ($0.09/shr) vs $6.6M ($0.19/shr) YoY; adjusted EBITDA loss $2.0M vs $4.3M.
Soft launch of AYON Body Contouring System exceeding expectations; commercial launch planned September 2025.
Renuvion launched in China via partner GlamMoon; initial procedures completed with strong clinical interest.
FY2025 revenue guidance raised to $50-52M (from $47.6-49M); Advanced Energy guidance $42-44M.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.